BioSpace News Archive

Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options to new employees as an inducement award outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.

Sutro Biopharma, Inc., a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates, announced that on August 16, 2022, the Compensation Committee of Sutro’s Board of Directors granted 63,000 Restricted Stock Units of Sutro common stock to three new employees.

Senti Biosciences, Inc. announced that on August 18, 2022, the compensation committee of Senti Bio’s board of directors granted to thirty five new employees stock options to purchase an aggregate of 421,659 shares of the Company’s common stock with a per share exercise price of $1.99.

PacBio announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 475,000 shares of PacBio common stock to the Company’s recently hired Chief Commercial Officer, Jeff Eidel, under the Pacific Biosciences 2020 Inducement Equity Incentive Plan, effective on August 16, 2022.

Veru Inc. today announced the appointment of Jason Davies as Executive Vice President – General Manager of Europe, the Middle East and Africa (EMEA), Latin America (LATAM), and Asia Pacific (APAC) for Veru’s Infectious Disease Franchise for Veru International.

Verismo Therapeutics today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) requesting approval to initiate its first-in-human Phase 1 clinical trial of SynKIR-110 in patients with mesothelin-expressing ovarian cancer, mesothelioma and cholangiocarcinoma.

Moleculin Biotech, Inc. today reported preliminary results from the third cohort of the Company’s first-in-human Phase 1a study of WP1122.

Government of Canada officials will provide an update on COVID-19 and be available to address other public health concerns.

The growing influence of technology across the life science research, molecular diagnostics, and forensics will boost the growth of the nucleic acid isolation and purification market through the assessment period of 2020-2030.

Over the past decade, neurointerventional techniques have gained increased significance in the management of acute ischemic strokes.